Gastrointestinal Stromal Tumor (GIST)

+ -Text Size

Other Resources and References TOPICS

References: Gastrointestinal stromal tumor detailed guide

American Joint Committee on Cancer. Gastrointestinal stromal tumors. In: AJCC Cancer Staging Manual. 7th ed. New York, NY: Springer; 2010:175-180.

Benjamin R, Pisters PW, Helman LJ, Bramwell VH, Rubin BP, O’Sullivan B. Sarcomas of soft tissue. In: Abeloff MD, Armitage JO, Niederhuber JE, Kastan MB, McKenna WG, eds. Abeloff’s Clinical Oncology. 4th ed. Philadelphia, Pa: Elsevier; 2008:2009–2056.

Blay JY, von Mehren M, Blackstein ME. Perspective on updated treatment guidelines for patients with gastrointestinal stromal tumors. Cancer. 2010;116:5126-5137.

Corless CL, Heinrich MC, Fletcher JA. Biology of gastrointestinal stromal tumors. J Clin Oncol. 2004;22:3813-3825.

Dematteo RP, Ballman KV, Antonescu CR, et al; American College of Surgeons Oncology Group (ACOSOG) Intergroup Adjuvant GIST Study Team. Adjuvant imatinib mesylate after resection of localised, primary gastrointestinal stromal tumour: A randomised, double-blind, placebo-controlled trial. Lancet. 2009;373:1097-1104.

Demetri GD, Reichardt P, Kang YK, et al. Efficacy and safety of regorafenib for advanced gastrointestinal stromal tumours after failure of imatinib and sunitinib (GRID): an international, multicentre, randomised, placebo-controlled, phase 3 trial. Lancet. 2013 Jan 26;381(9863):295-302.. Epub 2012 Nov 22.

Demetri GD. Gastrointestinal stromal tumors. In: DeVita VT, Lawrence TS, Rosenberg SA, eds. DeVita, Hellman, and Rosenberg’s Cancer: Principles and Practice of Oncology. 9th ed. Philadelphia, Pa: Lippincott Williams & Wilkins; 2011:1060-1073.

Heinrich MC, Corless CL, Demetri GD, et al. Kinase mutations and imatinib response in patients with metastatic gastrointestinal stromal tumor. J Clin Oncol. 2003;21:4342-4349.

Joensuu H, Eriksson M, Hatrmann J, et al. Twelve versus 36 months of adjuvant imatinib (IM) as treatment of operable GIST with a high risk of recurrence: Final results of a randomized trial (SSGXVIII/AIO). J Clin Oncol (Meeting Abstracts) June 2011 vol. 29 no. 18_suppl LBA1.

Li FP, Fletcher JA, Heinrich MC, et al. Familial gastrointestinal stromal tumor syndrome: Phenotypic and molecular features in a kindred. J Clin Oncol. 2005; 23:2735-2743.

Lin SC, Huang MJ, Zeng CY, et al. Clinical manifestations and prognostic factors in patients with gastrointestinal stromal tumors. World J Gastroenterol. 2003;9:2809-2812.

National Cancer Institute. Physician Data Query (PDQ). Gastrointestinal Stromal Tumors Treatment. 2012. Accessed at on October 31, 2012.

National Comprehensive Cancer Network (NCCN). NCCN Clinical Practice Guidelines in Oncology: Soft Tissue Sarcoma. V.2.2012. Accessed at on October 31, 2012.

Nilsson B, Bumming P, Meis-Kindblom JM, et al. Gastrointestinal stromal tumors: The incidence, prevalence, clinical course and prognostication in the pre-imatinib mesylate era. Cancer. 2005;103:821-829.

Perez EA, Livingstone AS, Franceschi D, et al. Current incidence and outcomes of gastrointestinal mesenchymal tumors including gastrointestinal stromal tumors. J Am Coll Surg. 2006;202:623–629.

Raut CP, Morgan JA, Ashley SW. Current issues in gastrointestinal stromal tumors: Incidence, molecular biology, and contemporary treatment of localized and advanced disease. Current Opin Gastroenterol. 2007;23:149-158.

Tran T, Davila JA, El-Serag HB. The epidemiology of malignant gastrointestinal stromal tumors: An analysis of 1,458 cases from 1992-2000. Am J Gastroenterol. 2005;100:162-168.

Van der Zwan SM, DeMatteo RP. Gastrointestinal stromal tumor: 5 years later. Cancer. 2005;104:1781-1788.

Last Medical Review: 12/11/2012
Last Revised: 02/26/2013